Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2

被引:89
作者
Adamec, E
Mohan, P
Vonsattel, JP
Nixon, RA
机构
[1] Harvard Univ, Sch Med, Dept Psychiat, Mailman Res Ctr,McLeans Hosp, Belmont, MA 02478 USA
[2] NYU, Sch Med, Dept Psychiat, Orangeburg, NY 10962 USA
[3] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[4] NYU, Sch Med, Dept Cell Biol, Orangeburg, NY 10962 USA
[5] Columbia Univ, Sch Med, Dept Pathol, Columbia Presbyterian Med Ctr, New York, NY 10032 USA
关键词
calpain; Alzheimer's disease; neurodegeneration; proteolysis; confocal microscopy;
D O I
10.1007/s00401-002-0528-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The calcium-activated protease calpain cleaves a variety of biologically important proteins and serves, therefore, as a key regulator of many cellular functions. Activation of both main isoforms, calpain 1 and calpain 2, was demonstrated previously in Alzheimer's disease. In this report, antibodies specifically recognizing the active form of calpain 2 were used to investigate calpain 2 activation in a broad range of neurodegenerative diseases, utilizing multiple-label confocal immunofluorescence imaging. With rare exceptions, the active form of calpain 2 was found in colocalization with hyperphosphorylated tau protein. Aggregates of mutated huntingtin, (x-synuclein, or unidentified protein in motor neuron disease type of frontotemporal dementia were always negative. These findings indicate that calpain 2 activation is not a general response to protein aggregation. In tauopathies, more pathological inclusions were labeled for hyperphosphorylated tau than for activated calpain 2. The extent of colocalization varied in both a disease-specific and cell-type specific manner. The active form of calpain 2 was detected in 50-75% of tau neurofibrillary pathology in Alzheimer's disease, Alzheimer neurofibrillary changes and Down's syndrome, as well as in the accompanying Alzheimer-type tau pathology in diffuse Lewy bodies disease, progressive supranuclear palsy, and corticobasal degeneration. For glial cells, only 10-25% of tuft-shaped astrocytes, glial plaques, or coiled bodies contained activated calpain 2. The majority of Pick bodies were negative. The association of calpain 2 activation with hyperphosphorylated tau might be the result of an attempt by the calpain proteolytic system to degrade the tau protein aggregates. Alternatively, calpain 2 could be directly involved in tau hyperphosphorylation by modulating protein kinase activities. Overall, these results provide evidence of the important role of the calpain proteolytic system in the pathogenesis of neurodegenerative diseases with tau neurofibrillary pathology.
引用
收藏
页码:92 / 104
页数:13
相关论文
共 82 条
  • [41] DIFFERENTIAL SENSITIVITY PROTEOLYSIS BY BRAIN CALPAIN OF ADULT HUMAN-TAU, FETAL HUMAN-TAU AND PHF-TAU
    MERCKEN, M
    GRYNSPAN, F
    NIXON, RA
    [J]. FEBS LETTERS, 1995, 368 (01) : 10 - 14
  • [42] THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .2. STANDARDIZATION OF THE NEUROPATHOLOGIC ASSESSMENT OF ALZHEIMERS-DISEASE
    MIRRA, SS
    HEYMAN, A
    MCKEEL, D
    SUMI, SM
    CRAIN, BJ
    BROWNLEE, LM
    VOGEL, FS
    HUGHES, JP
    VANBELLE, G
    BERG, L
    [J]. NEUROLOGY, 1991, 41 (04) : 479 - 486
  • [43] UBIQUITIN IS A COMPONENT OF PAIRED HELICAL FILAMENTS IN ALZHEIMERS-DISEASE
    MORI, H
    KONDO, J
    IHARA, Y
    [J]. SCIENCE, 1987, 235 (4796) : 1641 - 1644
  • [44] UBIQUITIN IS CONJUGATED WITH AMINO-TERMINALLY PROCESSED TAU IN PAIRED HELICAL FILAMENTS
    MORISHIMAKAWASHIMA, M
    HASEGAWA, M
    TAKIO, K
    SUZUKI, M
    TITANI, K
    IHARA, Y
    [J]. NEURON, 1993, 10 (06) : 1151 - 1160
  • [45] Calpain activity in the rat brain after transient forebrain ischemia
    Neumar, RW
    Meng, FH
    Mills, AM
    Xu, YA
    Zhang, C
    Welsh, FA
    Siman, R
    [J]. EXPERIMENTAL NEUROLOGY, 2001, 170 (01) : 27 - 35
  • [46] TAU-RELATED PROTEIN PRESENT IN PAIRED HELICAL FILAMENTS HAS A DECREASED TUBULIN BINDING-CAPACITY AS COMPARED WITH MICROTUBULE-ASSOCIATED PROTEIN TAU
    NIETO, A
    CORREAS, I
    LOPEZOTIN, C
    AVILA, J
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1096 (03) : 197 - 204
  • [47] Nixon RA, 2000, ANN NY ACAD SCI, V924, P117
  • [48] NIXON RA, 1994, ANN NY ACAD SCI, V747, P77
  • [49] DIFFERENCE BETWEEN THE TAU-PROTEIN OF ALZHEIMER PAIRED HELICAL FILAMENT CORE AND NORMAL TAU REVEALED BY EPITOPE ANALYSIS OF MONOCLONAL ANTIBODIES-423 AND ANTIBODIES-7.51
    NOVAK, M
    JAKES, R
    EDWARDS, PC
    MILSTEIN, C
    WISCHIK, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) : 5837 - 5841
  • [50] MONOCLONAL-ANTIBODY PHF-1 RECOGNIZES TAU-PROTEIN PHOSPHORYLATED AT SERINE RESIDUE-396 AND RESIDUE-404
    OTVOS, L
    FEINER, L
    LANG, E
    SZENDREI, GI
    GOEDERT, M
    LEE, VMY
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 1994, 39 (06) : 669 - 673